EGFR and non-small cell lung carcinoma: These results indicate that M-COPA exerts in vivo antitumor activity against first- and third-generation EGFR-TKI-resistant NSCLC cells xenografted into nude mice, and that this class of compound might be useful for the treatment of NSCLC patient in the clinic.